Fly News Breaks for February 11, 2020
Feb 11, 2020 | 10:56 EDT
Exelixis last night reported interim Phase Ib COSMIC-021 expansion data of Cabometyx with atezolizumab in 44 men with metastatic castration-resistant prostate cancer showing an "impressive" 32% objective response rate and 80% disease control rate with 8.3 month median duration of response, Piper Sandler analyst Edward Tenthoff tells investors in a research note. The analyst believes these data support Exelixis' plan to file for accelerated approval metastatic castration-resistant prostate cancer in early 2021. He reiterates an Overweight rating on the shares with a $35 price target.
News For EXEL From the Last 2 Days